REG - ReNeuron Group plc - Notification of Interim Results <Origin Href="QuoteRef">RQE.L</Origin>

ReNeuronAnnouncement

13/11/2017 11:35

RNS Number : 3245W
ReNeuron Group plc
13 November 2017
13 November 2017
AIM: RENE
ReNeuron Group plc
("ReNeuron" or "the Company")
Notification of Interim Results
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, intends to announce its interim results for the six months ended 30 September 2017 on Thursday 14 December 2017.
A meeting for analysts will be held at 9.30am on the morning of 14 December 2017 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 9.30am on the day of the results:
http://vm.buchanan.uk.com/2017/reneuron141217/registration.htm
A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.
ENQUIRIES:
ReNeuron
+44 (0)20 3819 8400
Olav Helleb , Chief Executive Officer

Michael Hunt, Chief Financial Officer

Buchanan
+44 (0) 20 7466 5000
Mark Court, Sophie Wills, Stephanie Watson



Stifel Nicolaus Europe Limited
+44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

N+1 Singer Advisory LLP
+44 (0) 20 7496 3000
Mark Taylor (Joint Broker)

About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NOREAFFDFAAXFFF